RESEARCH ARTICLE

Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification

Sasha S. Bjergfelt1, Ida M. H. Sørensen1, Henrik Ø. Hjortkjær2, Nino Landler3, Ellen L. F. Ballegaard1, Tor Biering-Sørensen3, Klaus F. Kofoed2, Theis Lange4, Bo Feldt-Rasmussen1, Henrik Sillese5, Christina Christoffersen6,7, Susanne Bro1*

1 Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
2 Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
3 Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark,
4 Department of Public Health (Biostatistics), University of Copenhagen, Copenhagen, Denmark,
5 Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
6 Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,
7 Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

* susanne.bro@regionh.dk

Abstract

Background

Chronic kidney disease accelerates both atherosclerosis and arterial calcification. The aim of the present study was to explore whether maximal carotid plaque thickness (cPTmax) was increased in patients with chronic kidney disease compared to controls and associated with cardiovascular disease and severity of calcification in the carotid and coronary arteries.

Methods

The study group consisted of 200 patients with chronic kidney disease stage 3 from the Copenhagen Chronic Kidney Disease Cohort and 121 age- and sex-matched controls. cPTmax was assessed by ultrasound and arterial calcification by computed tomography scanning.

Results

Carotid plaques were present in 58% of patients (n = 115) compared with 40% of controls (n = 48), p = 0.002. Among participants with plaques, cPTmax (median, interquartile range) was significantly higher in patients compared with controls (1.9 (1.4–2.3) versus 1.5 (1.2–1.8) mm), p = 0.001. Cardiovascular disease was present in 9% of patients without plaques (n = 85), 23% of patients with cPTmax 1.0–1.9 mm (n = 69) and 35% of patients with cPTmax >1.9 mm (n = 46), p = 0.001. Carotid and coronary calcium scores >400 were present in 0% and 4%, respectively, of patients with no carotid plaques, in 19% and 24% of patients with cPTmax 1.0–1.9 mm, and in 48% and 53% of patients with cPTmax >1.9 mm, p<0.001.
Conclusions

This is the first study showing that cPTmax is increased in patients with chronic kidney disease stage 3 compared to controls and closely associated with prevalent cardiovascular disease and severity of calcification in both the carotid and coronary arteries.

Introduction

Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular disease [1–5]. Indeed, patients with CKD are far more likely to die from cardiovascular disease than progress to end stage kidney disease requiring dialysis or kidney transplantation [6]. Early diagnosis of cardiovascular disease in patients with CKD is challenging, since these patients do not demonstrate typical clinical symptoms [7]. Moreover, prediction of future cardiovascular disease based on classical risk scoring systems underestimates the risk in patients with CKD [8]. An alternative approach for predicting symptomatic cardiovascular disease is based on the assessment of asymptomatic vascular disease using coronary artery calcium score (CACS) and carotid ultrasound imaging techniques. CACS seems to predict future cardiovascular disease for the individual person in the general population much better than risk-factor based scoring systems [9, 10]. Quantification of plaque size from both carotids by ultrasound has a similar predictive value as CACS in the general population [11]. Accordingly, a recent study of 6102 asymptomatic (non-CKD) persons showed that measurement by ultrasound of the simpler maximal carotid plaque thickness (cPTmax) predicted cardiovascular events similarly to the more comprehensive carotid plaque burden estimates [12].

Also in CKD, CACS provides additional value beyond existing clinical risk factor scoring systems [13–16]. So far, only few prospective ultrasound studies of the carotid artery have been performed in the CKD setting, and they used different methods for assessment of carotid atherosclerosis [17, 18]. The present study is the first to evaluate cPTmax in patients with CKD. The primary aim was to examine whether cPTmax is increased in patients with CKD stage 3 compared with controls and associated with prevalent cardiovascular disease. The secondary aim was to explore the association between cPTmax and the severity of calcification in the carotid and coronary arteries in CKD patients.

Materials and methods

Study population

The present carotid ultrasound study was a cross-sectional baseline study of a sub-group of patients from the Copenhagen (CPH) CKD Cohort described in details elsewhere [19]. In brief, the CPH CKD Cohort is a single-centre prospective, observational study examining novel risk factors and imaging methods for early detection of cardiovascular disease in a cohort of patients aged 30–75 years with any diagnosis of CKD stages 1–5 (no dialysis). CKD and CKD stages were defined in accordance with the 2012 Kidney Disease Improving Global Outcomes Guidelines [20]. The estimated glomerular filtration rate (eGFR) used to define eligibility was based on a measured plasma creatinine value and the CKD-EPIcrrea formula [21]. In total, 741 patients with CKD, 62 (8%) at stage 1, 115 (16%) at stage 2, 375 (51%) at stage 3, 146 (20%) at stage 4, and 43 (6%) at stage 5, were enrolled consecutively from the nephrology
outpatient clinic at Rigshospitalet, CPH University Hospital, Denmark, between 2015 and 2017.

Among included patients, 580 accepted to undergo computed tomography (CT) scanning of the major arterial regions: The carotid and coronary arteries, the thoracic and abdominal aorta and the iliac arteries [19]. The carotid ultrasound study was restricted to patients with CKD stage 3 (eGFR 30–59 ml/min per 1.73 m$^2$). This group was selected based on the hypothesis that identification of vascular disease in early CKD through screening programs may potentially maximize the effects of intervention to reduce progression of cardiovascular disease. Eligible patients from the CPH CKD Cohort were contacted and included consecutively until the number of 200 was reached.

Controls for the CPH CKD study were recruited by posting notices on the web-site “forsoegsperson.dk” and in local newspapers. The inclusion criteria were age 30–75 years, no history of cardiovascular disease, CKD, or other chronic or malignant disease. The exclusion criteria were eGFR <60 or kidney damage. The presence of well-treated mild hypertension (maximum 1 antihypertensive drug), thyroid disease and mild depression as well as hypercholesterolemia with or without statin treatment was accepted. From February to August 2017, we recruited a total of 175 controls who met the criteria and were sex- and age-matched at group level with the CPH CKD Cohort. Among these, a subgroup of 121 controls were selected to secure an optimal age and sex match at group level with the CKD patients undergoing ultrasound examination of the carotid arteries.

The study followed the principles of the Declaration of Helsinki and was approved by the Regional Scientific Ethical Committee (H-3-2011-069) and the Danish Data Protection Agency (30–0840). All participants signed a written informed consent at inclusion.

Clinical data and biochemistry

Information on demographic and clinical data, medical history, medications and lifestyle factors were retrieved from in-person interviews, physical examination and electronic medical records [19]. Biochemical data were obtained from a fasting blood sample and a urine sample.

Cardiovascular disease was defined as a composite of prevalent coronary artery disease, a history with previous cerebrovascular infarction, carotid endarterectomy or stenting and/or peripheral artery disease as described in detail [19].

Measurement of cPTmax

Ultrasound examination of the carotid arteries was performed by the same person (SSB) with a Philips EPIQ 7C ultrasound system equipped with a L12-3 transducer (48 Hz). The scanning protocol included a cross-sectional 10 second video of the carotid artery on both sides as described in detail [12]. The transducer was moved in the cranial direction from the proximal common carotid artery, just above the clavicle, to the bifurcation and then following the internal carotid artery as far as possible. All videos were made with the transducer in a perpendicular angle to the arteries. To support the assessment of the videos, longitudinally imaging of the common carotid artery and its branches were made. The assessment of cPTmax was made manually by a single reader (SSB) using a Dicom viewer (Micro Dicom). cPTmax was measured by finding the thickest part of the plaque in the cross-sectional videos and then measuring the radial distance from the media–adventitia interface to the intima–lumen interface (Fig 1). Carotid plaque was defined as a focal structure encroaching into the arterial lumen of at least 0.5 mm, or 50% of the surrounding intima-media thickness value; or demonstrating a thickness $\geq$1.5 mm, as measured from the media-adventitia interface to the intima-lumen interface [22, 23]. For the statistical analysis
only the anatomical side with the highest \( cPT_{\text{max}} \) was used. Based on the distribution of \( cPT_{\text{max}} \), the subjects were divided into 3 groups: No plaques, \( cPT_{\text{max}} \) 1.0–1.9 mm and \( cPT_{\text{max}} > 1.9 \) mm (the median \( cPT_{\text{max}} \) in the CKD group was 1.9 mm). Intraobserver coefficient of variation (CV) was 9%. Re-examination of the videos for intra-observer variability testing (\( n = 30 \)) did not re-classify any of the patients.

**Assessment of carotid and coronary artery calcium scores**

Noncontrast electrocardiography-gated CT scans of the major arterial regions were performed with a 320-detector CT scanner (Aquillion One, Toshiba medical Systems, Japan). Calcification scoring was performed as previously described \[19, 24\]. Based on the distribution of Agatston scores in the selected arterial region, the subjects were divided into calcium score categories of 0 (no calcification), 1–100, 101–400, \( > 400 \) \[25\]. Images of inadequate quality were excluded. Intra-observer CV was 10%, interobserver CVs varied between 12–13% \[19\].

**Statistical analyses**

Statistical analyses were performed using SPSS version 25 (IBM SPSS Statistics, New York, USA). A value of \( p < 0.05 \) was considered statistically significant. Categorical variables are presented as \( n (\%) \) and were compared using the chi-square test. Totals may not add up to 100% due to rounding. Continuous variables were presented as means ± standard error of the means (SE) for normally distributed data and compared using the t-test, whereas skewed data were reported as median [interquartile range (IQR)] and compared using the Mann-Whitney U test or the Kruskal-Wallis test, when more than 2 groups were compared.
Results

Characteristics of the ultrasound study cohort

A total of 200 patients with CKD and 121 controls were enrolled (Table 1).

Among the patients, 21% had type 2 diabetes, 3% type 1 diabetes and 21% cardiovascular disease. A large proportion of the patients were on anti-hypertensive medication (84%), lipid lowering treatment (52%), and/or anti-platelet treatment (31%). Age and sex distribution were similar in patients with CKD and controls (Table 1). Controls had normal eGFR and no albuminuria. Among the controls, 29% had hypertension and 67% hypercholesterolemia.

Table 1. Demographic, clinical and laboratory characteristics of participants in the carotid ultrasound study.

| Variable                              | CKD patients | Controls | p-values |
|---------------------------------------|--------------|----------|----------|
| No. of participants (n)               | 200          | 121      |          |
| Age (yr)                              | 64 (54–71)   | 64 (52–70) | 0.366    |
| Female sex (n, %)                     | 76 (38)      | 49 (41)  | 0.657    |
| BP systolic (mmHg)                    | 133 (±1)     | 130 (±2) | 0.228    |
| BP diastolic (mmHg)                   | 80 (±1)      | 81 (±1)  | 0.451    |
| P-creatinine (μmol/l)                 | 142 (123–165)| 79 (70–89) | <0.001   |
| eGFR (ml/min/1.73m²)                  | 41 (35–50)   | 82 (75–92)| <0.001   |
| P-HDL-cholesterol (mmol/l)            | 1.52 (±0.04) | 1.82 (±0.05) | <0.001   |
| P-LDL-cholesterol (mmol/l)            | 3.0 (±0.1)   | 3.5 (±0.1) | <0.001   |
| P-triglycerides (mmol/l)              | 1.55 (1.13–2.27)| 0.88 (0.69–1.15) | <0.001   |
| P-glucose (mmol/l)                    | 6.3 (±0.1)   | 5.8 (±0.0) | 0.006    |
| P-ionized calcium (mmol/l)            | 1.22 (±0.00) | 1.23 (±0.00) | 0.548    |
| P-phosphate (mmol/l)                  | 1.02 (±0.01) | 1.01 (±0.02) | 0.609    |
| Urine albumin/creatinine ratio x 10⁻³ | 67(10–352)   | 0 (0–4)  | <0.001   |
| Purate (mmol/l)                       | 0.44 (±0.01) | 0.31 (±0.01) | <0.001   |
| Hypertension (n, %)                   | 178 (89)     | 35 (29)  | <0.001   |
| Hypercholesterolemia (n, %)           | 162 (82)     | 81 (67)  | 0.002    |
| Type 1 diabetes (n, %)                | 6 (3)        | 0 (0)    | <0.001   |
| Type 2 diabetes (n, %)                | 42 (21)      | 0 (0)    |          |
| Cardiovascular co-morbidity (n, %)    | 41 (21)      | 0 (0)    | <0.001   |
| Cardiovascular disease and diabetes   | 18 (9)       | 0 (0)    | <0.001   |
| (n, %)                                |              |          |          |
| Alcohol intake (units/week)           | 2 (0–10)     | 7 (3–14) | <0.001   |
| Smoking status (n, %):                |              |          |          |
| Never smoked                          | 78 (39)      | 63 (52)  | 0.028    |
| Former smoker                         | 82 (41)      | 45 (37)  |          |
| Active smoker                         | 40 (20)      | 13 (11)  |          |
| Smoking (pack years)                  | 5 (0–30)     | 0 (0–10) | <0.001   |
| Medication (n, %):                    |              |          |          |
| Lipid lowering                        | 104 (52)     | 0 (0)    | <0.001   |
| Anti-hypertensive                     | 168 (84)     | 0 (0)    | <0.001   |
| Insulin                               | 23 (12)      | 0 (0)    | <0.001   |
| Oral antidiabetic                     | 23 (12)      | 0 (0)    | <0.001   |
| Anti-platelet                         | 62 (31)      | 2 (2)    | <0.001   |

Values for categorical variables are given as number (percentages), totals may not add up to 100% due to rounding; values for continuous variables are given as mean (±SEM) or median (IQR, 25th to 75th percentile). CKD: chronic kidney disease. BP: blood pressure. eGFR: estimated glomerular filtration rate.

https://doi.org/10.1371/journal.pone.0260417.t001
diagnosed at inclusion. None received antihypertensive or cholesterol-lowering therapy. Two controls received anti-platelet therapy, but none of them had known cardiovascular disease.

cPTmax in patients with CKD stage 3 and controls

Plaques were present in 58% of patients with CKD stage 3 (n = 115) as compared to 40% of controls (n = 48), \( p = 0.002 \). Among participants with plaques, the median (IQR) cPTmax was significantly higher in patients as compared with the controls (1.9 (1.4–2.3) versus 1.5 (1.2–1.8) mm), \( p = 0.001 \) (Fig 2). Comparing patients with plaques but without prevalent cardiovascular disease (n = 82) with controls (n = 48), the difference was still significant (1.7 (1.4–2.2) versus 1.5 (1.2–1.8) mm), \( p = 0.01 \).

Association between cPTmax and prevalent cardiovascular disease

Cardiovascular disease was present in 9% of patients without plaques, 23% of patients with cPTmax 1.0–1.9 mm, and 35% of patients with cPTmax >1.9 mm, \( p = 0.002 \) (Table 2). Among patients with plaques, median cPTmax was 2.0 (1.6–2.8) mm in patients with prevalent cardiovascular disease.
Table 2. Characteristics of patients with CKD grouped according to plaque status.

| Variable                              | No plaques | cPTmax 1.0–1.9 mm | cPTmax >1.9 mm | p-values (Plaques present vs. absent) |
|----------------------------------------|------------|-------------------|----------------|--------------------------------------|
| No. of participants (n)                | 85         | 69                | 46             |                                      |
| Age (yr)                               | 54 (44–62) | 67 (61–72)        | 70 (65–72)     | <.0001                               |
| Female sex, n, %                       | 43 (51)    | 26 (38)           | 6 (13)         | .001                                 |
| BMI (kg/m²)                            | 28.0 (±0.7) | 29.2 (±0.8)      | 29.5 (±0.8)    | .131                                 |
| Abdominal circumference (cm)           | 96.5 (±2.1) | 104.0 (±2.0)     | 107.9 (±2.3)   | <.0001                               |
| BP systolic (mmHg)                     | 130 (±2)   | 137 (±2)          | 134 (±3)       | .025                                 |
| BP diastolic (mmHg)                    | 83 (±1)    | 81 (±1)           | 76 (±2)        | .015                                 |
| P-creatinine (μmol/l)                  | 138 (120–163) | 139 (120–162) | 151 (126–170) | .474                                 |
| eGFR (ml/min/1.73m²)                   | 41 (36–52) | 42 (35–50)        | 40 (34–44)     | .175                                 |
| P-HDL-cholesterol (mmol/l)             | 3.2 (±0.1) | 2.9 (±0.1)        | 2.6 (±0.1)     | .003                                 |
| P-triglycerides (mmol/l)               | 1.52 (1.14–2.23) | 1.59 (1.09–2.33) | 1.56 (1.20–2.17) | .942                                 |
| P-glucose (mmol/l)                     | 5.8 (±0.1) | 6.5 (±0.2)        | 6.8 (±0.4)     | .004                                 |
| P-ionic calcium (mmol/l)               | 1.23 (±0.01) | 1.22 (±0.01) | 1.22 (±0.01) | .835                                 |
| P-phosphate (mmol/l)                   | 1.03 (±0.02) | 1.02 (±0.02) | 1.04 (±0.03) | .986                                 |
| Urine albumin/creatinine ratio x 10⁻³  | 70 (11–331) | 47 (7–343)        | 125 (31–639)   | .506                                 |
| P-urate (mmol/l)                       | 0.43 (±0.01) | 0.44 (±0.01) | 0.48 (±0.02) | .148                                 |
| Hypertension (n, %)                    | 74 (87)    | 62 (90)           | 43 (94)        | .333                                 |
| Hypercholesterolemia (n, %)            | 65 (77)    | 60 (87)           | 38 (83)        | .118                                 |
| Diabetes (n, %):                       |            |                   |                | .001                                 |
| Type 1 diabetes                        | 3 (4)      | 2 (3)             | 1 (2)          |                                      |
| Type 2 diabetes                        | 7 (8)      | 20 (29)           | 15 (33)        |                                      |
| Cardiovascular-comorbidity (n, %)      | 8 (9)      | 16 (23)           | 16 (35)        | .002                                 |
| Alcohol intake (units/week)            | 1 (0–6)    | 4 (0–14)          | 3 (1–12)       | .087                                 |
| Smoking status (n, %)                  |            |                   |                | .010                                 |
| Never smoked                           | 42 (49)    | 23 (33)           | 13 (28)        |                                      |
| Former smoker                          | 33 (39)    | 29 (42)           | 20 (44)        |                                      |
| Active smoker                          | 10 (12)    | 17 (25)           | 13 (28)        |                                      |
| Smoking (pack years)                   | 1 (0–15)   | 10 (0–38)         | 28 (0–50)      | <.0001                               |
| Medication (n, %):                     |            |                   |                |                                      |
| Lipid lowering                         | 32 (38)    | 41 (59)           | 31 (67)        | <.0001                               |
| Anti-hypertensive                      | 70 (82)    | 56 (81)           | 42 (91)        | .585                                 |
| Insulin                                | 6 (7)      | 6 (9)             | 11 (24)        | .091                                 |
| Oral anti-diabetic                     | 2 (2)      | 14 (20)           | 7 (15)         | <.0001                               |
| Anti-platelet                          | 10 (12)    | 25 (36)           | 27 (59)        | <.0001                               |
| cPT max, mm*                           | NR         | 1.5 (1.3–1.7)     | 2.4 (2.2–2.9)  | NR                                   |
| Coronary calcium score                 | 0 (0–38)   | 76 (0–378)        | 507 (87–1012)  | <.0001                               |
| Carotid calcium score                  | 0 (0–3)    | 88 (10–252)       | 356 (153–1104) | <.0001                               |

Values for categorical variables are given as number (percentages), totals may not add up to 100% due to rounding; values for continuous variables are given as mean (±SEM) or median (IQR, 25th to 75th percentile). BMI: body mass index. BP: blood pressure. eGFR: estimated glomerular filtration rate. cPT max: maximal carotid plaque thickness. NR: not relevant.

*p-PT max was only measured in patients with plaques.

https://doi.org/10.1371/journal.pone.0260417.t002

Cardiovascular disease (n = 32) versus 1.7 (1.4–2.2) mm in patients without cardiovascular disease (n = 83, p = 0.024). Table 2 demonstrates that patients with carotid plaques had a higher prevalence of multiple classical cardiovascular risk factors as compared with patients without plaques. Patients with diabetes (n = 48) showed a higher prevalence of plaques (79%) than
patients without diabetes (51%, n = 152), \( p < 0.001 \). Nevertheless, among patients with plaques, median cPTmax did not differ between patients with (n = 38) and without (n = 77) diabetes, \( p = 0.704 \). Likewise, patients with a smoking history showed a higher prevalence of plaques than patients who had never smoked (active, former and never smokers: 75%, 60%, and 46%, respectively), \( p = 0.010 \). However, among patients with plaques, median cPTmax did not differ between smoking status groups (\( p = 0.827 \)).

### Relation of cPTmax with carotid and coronary artery calcium scores

Fig 3 shows a strong association between cPTmax and carotid as well as coronary artery calcium scores. Carotid and coronary calcium scores \( > 400 \) were present in 0% and 4%, respectively, of patients with no carotid plaques, in 19% and 24% of patients with cPTmax 1.0–1.9 mm, and in 48% and 53% of patients with cPTmax \( > 1.9 \) mm, \( p < 0.001 \).

Fig 4 demonstrates that the association between cPTmax and carotid calcium score was maintained, when the CKD patients were grouped according to sex, age or smoking status, i.e. few or no patients with cPTmax \( > 1.9 \) mm in the calcium score 0 category and few or no patients with no plaques in the calcium score \( > 400 \) category. The same pattern was also seen when the patients were grouped according to presence/absence of hypertension, hypercholesterolemia and diabetes (S1 Fig). Similar data for the relation between cPTmax and coronary calcium score are shown in S2 and S3 Figs.

For comparison, in the thoracic aorta, abdominal aorta and iliac arteries, calcium scores \( > 400 \) were present in 20%, 26% and 25%, respectively, of patients with no carotid plaques (Fig 5).

### Discussion

The CPH CKD Cohort study is the first to examine cPTmax determined by ultrasound in patients with CKD. We demonstrated that both plaque prevalence and cPTmax were increased in patients with CKD stage 3 compared with controls. The increase of cPTmax in patients versus controls was maintained, when patients with CKD and prevalent cardiovascular disease were excluded. cPTmax was closely associated with prevalent cardiovascular disease and with calcification of the carotid and coronary arteries.

Increased prevalence of plaques in patients with CKD has been reported by others [26–28]. In the NEFRONA study, 70% of patients with CKD stage 3 had plaques in the carotid or femoral arterial regions compared with 52% of the controls [26]. Since 12% of patients and 10% of controls had plaques in the femoral arteries only, the prevalence of carotid plaques in patients with CKD stage 3 and controls was similar to the findings in our study. The NEFRONA study also reported that progression of atherosclerosis (i.e. number of territories with plaques) was associated with progression of CKD and that progression of atherosclerosis was delayed in patients with no plaques at baseline [29]. Finally, the NEFRONA follow-up study showed that the number of territories with plaques was a stronger predictor of cardiovascular events than the mere presence (versus absence) of plaques in the carotid and femoral arteries of patients with CKD (non-dialysis dependent) [17]. Carotid intima media thickness did not predict cardiovascular events. Another study of 101 patients on hemodialysis demonstrated that the sum of plaque thickness from each segment of the carotid artery on both sides predicted cardiovascular mortality after 4 years of follow-up [18]. These results indicate that quantification of plaque size improves the predictive power in the CKD population.

The presence of plaques in the present study was associated with multiple classical cardiovascular risk factors, and cPTmax was closely associated with prevalent cardiovascular disease. Also, the prevalence of plaques was higher in patients with diabetes, but with similar cPTmax
Fig 3. Association between maximal carotid plaque thickness (cPTmax) and carotid artery calcium score (A) and coronary artery calcium score (B). According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from noncontrast CT scanning of the carotid and coronary arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. The $p$-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).

https://doi.org/10.1371/journal.pone.0260417.g003
Fig 4. Association between maximal carotid plaque thickness (cPTmax) and carotid artery calcium score in patients with CKD stage 3. (A) In men versus women, (B) in smokers versus non-smokers, and (C) in patients aged ≤ 64 yrs. versus > 64 yrs. According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax > 1.9 mm. Based on the distribution of calcium scores from CT scanning of the carotid arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and > 400. Non-smokers are defined as patients with 0 smoking pack yrs. and smokers as patients with smoking pack yrs. > 0. Age 64 yrs. is the median age of the CKD patients. The p-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).

https://doi.org/10.1371/journal.pone.0260417.g004
Fig 5. Association between maximal carotid plaque thickness (cPTmax) and thoracic aortic calcium score (A), abdominal aortic calcium score (B) and iliac artery calcium score (C). According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from noncontrast CT scanning of the thoracic aorta, abdominal aorta and iliac arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. The p-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).

https://doi.org/10.1371/journal.pone.0260417.g005
in CKD patients with and without diabetes. A possible explanation of the latter could be that the patients had several risk factors in addition to diabetes, including renal failure, and that the number of patients with diabetes was relatively small.

Likewise, patients with a smoking history showed a higher prevalence of plaques than patients who had never smoked, but with a non-significant difference between the median cPTmax of active, former and never smokers. Most likely, this lack of a significant difference is due to the relatively small number of patients with plaques and different smoking status.

The close association between cPTmax and calcium scores in the coronary arteries does indeed support the idea that cPTmax may be usable as a measure of cardiovascular risk in CKD, since CACS seems to improve prediction of cardiovascular risk in CKD patients [13–16]. The association between cPTmax and carotid calcium was very similar to the association with coronary calcium. A small study of hemodialysis patients also showed that carotid plaque thickness correlated strongly with CACS [30], and the authors observed that if there were no plaques, there was also no coronary artery calcification. Although the association between plaque thickness and calcification was strong in our study, we did observe presence of carotid plaques without carotid or coronary calcification in some patients (12 and 22, respectively) and calcification without plaques in others (19 and 24, respectively). This is not surprising, however, since early plaques are not calcified, and since media calcification not related to atherosclerosis is common in CKD (although more common in more advanced CKD). Unfortunately, intimal and medial calcification are indistinguishable by CT scanning. The close association between cPTmax and coronary (and carotid) calcium score suggests that most arterial calcium is localized in the intima of these arteries in patients with CKD stage 3. Interestingly, the association between cPTmax and calcium score categories was markedly less when the thoracic and abdominal aorta and the iliac arteries were considered. Thus, 20–26% of patients showed calcium scores >400 in these arterial regions, even if carotid plaques were absent. In comparison, no patients without carotid plaques showed carotid artery calcium scores >400, and only 4% of these patients showed coronary artery calcium scores >400. This suggests that non-intimal calcification i.e. medial calcification may be more pronounced in the aorta and the iliac arteries. However, since we did not measure PTmax in the femoral arteries, this hypothesis cannot be confirmed or rejected by the available data.

Ultrasound examination of the carotid arteries alone is more convenient and socially acceptable and less time-consuming than ultrasound scanning of both the carotid and femoral arteries. cPTmax is easier to measure than plaque volume, meaning that cPTmax measurements could be performed in a routine ultrasound laboratory. A follow-up study in the CKD Cohort will be needed to confirm the findings from the general population that cPTmax alone predicts cardiovascular risk similarly to CACS.

We recognize that the present study had some limitations. Carotid plaque burden was not measured for comparison with cPTmax. The cross-sectional nature of the study did not allow us to evaluate the predictive value of cPTmax. The main strengths of this study include that it is the first study measuring cPTmax in patients with CKD. We had a large control group. Vascular explorations were performed and evaluated by the same person, thus minimizing measurement variability. cPTmax data were compared with a validated method for cardiovascular risk scoring (CACS).

In conclusion, this is the first study to show that cPTmax is increased in patients with CKD stage 3 and closely associated with prevalent cardiovascular disease and calcification in both the carotid and coronary arteries.
Supporting information

S1 Fig. Association between maximal carotid plaque thickness (cPTmax) and carotid artery calcium score in patients with CKD stage 3. (A) In patients with and without hypertension, (B) in patients with and without hypercholesterolemia, and (C) in patients with and without diabetes. According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from CT scanning of the carotid arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. Hypertension was defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg or use of oral antihypertensive treatment. Hypercholesterolemia was defined as low-density lipoprotein (LDL) cholesterol >3 mmol/l or treatment with cholesterol-lowering medication. Diabetes: Type 1 or type 2 diabetes. The \( p \)-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).

(TIF)

S2 Fig. Association between maximal carotid plaque thickness (cPTmax) and coronary artery calcium score in patients with CKD stage 3. (A) In men versus women, (B) in smokers versus non-smokers, and (C) in patients aged \( \leq 64 \) yrs. versus \( > 64 \) yrs. According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from CT scanning of the coronary arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. Non-smokers are defined as patients with 0 smoking pack yrs. and smokers as patients with smoking pack yrs. > 0. Age 64 yrs. is the median age of the CKD patients. The \( p \)-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).

(TIF)

S3 Fig. Association between maximal carotid plaque thickness (cPTmax) and coronary artery calcium score in patients with CKD stage 3. (A) In patients with and without hypertension, (B) in patients with and without hypercholesterolemia, and (C) in patients with and without diabetes. According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from CT scanning of the coronary arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. Hypertension was defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg or use of oral antihypertensive treatment. Hypercholesterolemia was defined as low-density lipoprotein (LDL) cholesterol >3 mmol/l or treatment with cholesterol-lowering medication. Diabetes: Type 1 or type 2 diabetes. The \( p \)-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).

(TIF)

Acknowledgments

We thank the participants for their invaluable contribution to the study. Freja A. K. Saurbrey is thanked for help with Fig 1.

Author Contributions

Conceptualization: Sasha S. Bjergfelt, Bo Feldt-Rasmussen, Henrik Sillesen, Christina Christophersen, Susanne Bro.
Data curation: Sasha S. Bjergfelt, Ida M. H. Sørensen.
Formal analysis: Sasha S. Bjergfelt.
Funding acquisition: Bo Feldt-Rasmussen.
Investigation: Sasha S. Bjergfelt, Ida M. H. Sørensen, Henrik Ø. Hjortkjær, Nino Landler, Ellen L. F. Ballegaard, Tor Biering-Sørensen.
Methodology: Sasha S. Bjergfelt, Klaus F. Kofoed, Theis Lange, Henrik Sillesen.
Project administration: Bo Feldt-Rasmussen, Susanne Bro.
Resources: Bo Feldt-Rasmussen, Henrik Sillesen.
Supervision: Klaus F. Kofoed, Theis Lange, Bo Feldt-Rasmussen, Henrik Sillesen, Christina Christoffersen, Susanne Bro.
Validation: Susanne Bro.
Writing – original draft: Sasha S. Bjergfelt, Susanne Bro.
Writing – review & editing: Ida M. H. Sørensen, Henrik Ø. Hjortkjær, Nino Landler, Ellen L. F. Ballegaard, Tor Biering-Sørensen, Klaus F. Kofoed, Theis Lange, Bo Feldt-Rasmussen, Henrik Sillesen, Christina Christoffersen, Susanne Bro.

References
1. Gansevoort RT, Correa-Rotter R, Hemmeigarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382 (9898):339–52. https://doi.org/10.1016/S0140-6736(13)60595-4 PMID: 23727170
2. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006; 151(2):492–500. https://doi.org/10.1016/j.ahj.2005.03.055 PMID: 16442920
3. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003; 64(2):610–5. https://doi.org/10.1046/j.1523-1755.2003.00109.x PMID: 12946757
4. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007; 18(2):629–36. https://doi.org/10.1681/ASN.2005110144 PMID: 17215445
5. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007; 18(4):1307–15. https://doi.org/10.1681/ASN.2006101159 PMID: 1734421
6. Keith DS, Nichols GA, Guillon CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004; 164(6):659–63. https://doi.org/10.1001/archinte.164.6.659 PMID: 15037495
7. Sosnov J, Lessard D, Goldberg RJ, Yarzebski J, Gore JM. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis. 2006; 47 (3):378–84. https://doi.org/10.1053/ajkd.2005.11.017 PMID: 16496615
8. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007; 50(3):217–24. https://doi.org/10.1016/j.jacc.2006.12.020 PMID: 17631214
9. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012; 308(8):788–85. https://doi.org/10.1001/jama.2012.9624 PMID: 22910756
10. Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012; 156(6):438–44. https://doi.org/10.7326/0003-4819-156-6-201203200-00006 PMID: 22431676
11. Baber U, Mehran R, Sartori S, Schoos MM, Silesen H, Muntendam P, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults:
the Biomage study. J Am Coll Cardiol. 2015; 65(11):1065–74. https://doi.org/10.1016/j.jacc.2015.01.017 PMID: 25790876

12. Sillesen H, Sartori S, Sandholt B, Baber U, Mehran R, Fuster V. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur Heart J Cardiovasc Imaging. 2018; 19(10):1042–50. https://doi.org/10.1093/ehjci/jyx239 PMID: 29059296

13. Matsushita K, Sang Y, Bailee SH, Shlipak M, Katz R, Rosas SE, et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol. 2015; 26(2):439–47. https://doi.org/10.1681/ASN.2014020173 PMID: 25145930

14. Chan J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol. 2017; 2(6):635–43. https://doi.org/10.1001/jamacardio.2017.0363 PMID: 28329057

15. Chaikrianakis K, Nabi F, Mahmarian JJ, Chang SM. Additive prognostic value of coronary artery calcium score and renal function in patients with acute chest pain without known coronary artery disease: up to 5-year follow-up. Int J Cardiovasc Imaging. 2015; 31(8):1619–26. https://doi.org/10.1007/s10554-015-0732-9 PMID: 26243534

16. Lee JH, Rizvi A, Hartaigh BO, Han D, Park MW, Roudsari HM, et al. The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes: An International Multicenter [CONFIRM] Registry). Am J Cardiol. 2019; 123(9):1435–42. https://doi.org/10.1016/j.amjcard.2019.01.055 PMID: 30850210

17. Valdivielso JM, Betriu A, Martinez-Alonso M, Arroyo D, Bermudez-Lopez M, Fernandez E, et al. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. PLoS One. 2017; 12(10):e0186665. https://doi.org/10.1371/journal.pone.0186665 PMID: 29045466

18. Avramovski P, Avramovska M, Sikole A. B-flow imaging estimation of carotid and femoral atherosclerotic plaques: vessel walls rheological damage or strong predictor of cardiovascular mortality in chronic dialysis patients. Int Urol Nephrol. 2016; 48(10):1713–20. https://doi.org/10.1007/s11253-016-1393-x PMID: 27515315

19. Sorensen IMH, Saubrey SAK, Hjortkjaer HO, Brainin P, Carlson N, Ballegaard ELF, et al. Regional distribution and severity of arterial calcification in patients with chronic kidney disease stages 1–5: a cross-sectional study of the Copenhagen chronic kidney disease cohort. BMC Nephrol. 2020; 21(1):534. https://doi.org/10.1186/s12882-020-02192-y PMID: 33297991

20. Nephrology ISo. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2013; 3(1):150. https://doi.org/10.1038/kisup.2012

21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604–12. https://doi.org/10.7326/0003-4819-150-9-2009090500-00006 PMID: 19414839

22. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2010; 21(2):93–111; quiz 89–90. https://doi.org/10.1016/j.echo.2009.11.011 PMID: 18261694

23. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007; 23(1):75–80. https://doi.org/10.1055/s-0027-101199

24. Hjortkjaer HO, Jensen T, Hilsted J, Mogensen UM, Rossing P, Kober L, et al. Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy. Diab Vasc Dis Res. 2019; 16(1):98–102. https://doi.org/10.1177/1479164118805904 PMID: 30345796

25. Erbel R, Mohlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010; 56(17):1397–406. https://doi.org/10.1016/j.jacc.2010.06.030 PMID: 20946997

26. Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fernandez E, et al. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol. 2014; 15:168. https://doi.org/10.1186/1471-2369-15-168 PMID: 25326683
27. Coll B, Betriu A, Martinez-Alonso M, Borras M, Craver L, Amoedo ML, et al. Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrol Dial Transplant. 2010; 25(9):3017–25. https://doi.org/10.1093/ndt/gfq109 PMID: 20237061

28. Hsu S, Rifkin DE, Criqui MH, Suder NC, Garimella P, Ginsberg C, et al. Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease. J Vasc Surg. 2018; 67(6):1855–63 e1. https://doi.org/10.1016/j.jvs.2017.09.048 PMID: 29276107

29. Gracia M, Betriu A, Martinez-Alonso M, Arroyo D, Abajo M, Fernandez E, et al. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD. Clin J Am Soc Nephrol. 2016; 11(2):287–96. https://doi.org/10.2215/CJN.01240215 PMID: 26668022

30. Kurnatowska I, Grzelak P, Stefanczyk L, Nowicki M. Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients. Nephrology (Carlton). 2010; 15 (2):184–9. https://doi.org/10.1111/j.1440-1797.2009.01169.x PMID: 20470277